Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The target "novel transcript, antisense to SLC4A4" (ENSG00000306060) does not refer to a canonical protein, enzyme, transporter, or validated drug target. Instead, it likely denotes a putative or computationally predicted non-coding RNA transcribed from the DNA strand opposite to the SLC4A4 gene. The SLC4A4 gene (solute carrier family 4 member 4) encodes the electrogenic sodium bicarbonate cotransporter 1, involved in bicarbonate transport and pH regulation, and is a well-characterized membrane transporter protein[1][2][7]. No standard abbreviation, drug interactions, therapeutic relevance, or biological functions have been established for this antisense transcript, and there is no evidence that it represents a druggable target. This name also does not match known databases of gene or protein targets, further supporting that it is not currently a standard or actionable target in biomedical research.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on novel transcript, antisense to SLC4A4.